

Date: 25.04.2022 The Manager Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Scrip Code: 540359

Sub: Disclosure in pursuance of SEBI Circular No SEBI/HO/DDHS/CIR/P/2018/144 dated 26th November, 2018.

Dear Sir/Madam,

This is with reference to the above subject and SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/ 144 dated November 26, 2018 in respect of raising of funds by issuance of debt securities by Large Corporate (LC) and disclosures and compliances thereof by such Large Corporate.

In this regard, we would like to inform you that as on March 31, 2022 our company Parmax Pharma Limited is not falling under the category of "Large Corporate (LC)" as per the framework provided in the aforesaid Circular and therefore, the initial disclosure as per Annexure-A of the said circular is not applicable to the Company. You are requested to kindly find the above in order and arrange for updating of records accordingly.

Thanking You,

Yours Faithfully,

For Parmax Pharma Limited

Yash J. Vora

Company Secretary Contact Detail: 02827-270534/35/36 Email: <u>cs@parmaxpharma.com</u> For Parmax Pharma Limited

HADAMTA Keyur D. Vora

Chief Financial Officer Contact Detail: 02827-270534/35/36 Email: info@parmaxpharma.com

PARMAX PHARMA LIMITED

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail: info@parmaxpharma.com CIN: L24231GJ1994PLC023504